JACOBIO-B receives USD100.00 million upfront from AstraZeneca under pan-KRAS inhibitor licensing deal

Bulletin Express

03/30

Jacobio Pharmaceuticals Group Co., Ltd. (JACOBIO-B) disclosed that its indirect non-wholly owned subsidiary, Beijing Jacobio, has received an upfront payment of USD100.00 million from AstraZeneca AB. The payment forms part of the Licence and Collaboration Agreement signed on 21 December 2025 for the global development of the pan-KRAS inhibitor JAB-23E73.

According to the announcement dated 30 March 2026, the funds will increase the group’s cash reserves and support subsequent development of its oncology pipeline, which spans KRAS, STING, P53 and MYC pathways. Jacobio operates R&D centres in Beijing, Shanghai and Boston, leveraging its Induced Allosteric Drug Discovery Platform and immunostimulatory antibody-drug conjugate platform.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1114925187"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1114925187\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1114925187?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 08:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114925187","market":"us","top_or_hot":-1,"title":"JACOBIO-B receives USD100.00 million upfront from AstraZeneca under pan-KRAS inhibitor licensing deal","media":"Bulletin Express","content":"<p>Jacobio Pharmaceuticals Group Co., Ltd. (JACOBIO-B) disclosed that its indirect non-wholly owned subsidiary, Beijing Jacobio, has received an upfront payment of USD100.00 million from AstraZeneca AB. The payment forms part of the Licence and Collaboration Agreement signed on 21 December 2025 for the global development of the pan-KRAS inhibitor JAB-23E73.</p>\n<p>According to the announcement dated 30 March 2026, the funds will increase the group’s cash reserves and support subsequent development of its oncology pipeline, which spans KRAS, STING, P53 and MYC pathways. Jacobio operates R&D centres in Beijing, Shanghai and Boston, leveraging its Induced Allosteric Drug Discovery Platform and immunostimulatory antibody-drug conjugate platform.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JACOBIO-B receives USD100.00 million upfront from AstraZeneca under pan-KRAS inhibitor licensing deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJACOBIO-B receives USD100.00 million upfront from AstraZeneca under pan-KRAS inhibitor licensing deal\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-30 08:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Jacobio Pharmaceuticals Group Co., Ltd. (JACOBIO-B) disclosed that its indirect non-wholly owned subsidiary, Beijing Jacobio, has received an upfront payment of USD100.00 million from AstraZeneca AB. The payment forms part of the Licence and Collaboration Agreement signed on 21 December 2025 for the global development of the pan-KRAS inhibitor JAB-23E73.</p>\n<p>According to the announcement dated 30 March 2026, the funds will increase the group’s cash reserves and support subsequent development of its oncology pipeline, which spans KRAS, STING, P53 and MYC pathways. Jacobio operates R&D centres in Beijing, Shanghai and Boston, leveraging its Induced Allosteric Drug Discovery Platform and immunostimulatory antibody-drug conjugate platform.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01167","symbol_name":"加科思-B","start_time":0,"source_url":"","article_id":"1114925187","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114925187","pubTimestamp":1774829001,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jacobio Pharmaceuticals Group Co., Ltd. (JACOBIO-B) disclosed that its indirect non-wholly owned subsidiary, Beijing Jacobio, has received an upfront payment of USD100.00 million from AstraZeneca AB....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01167":"加科思-B"},"translate_title":"JACOBIO-B根据泛KRAS抑制剂许可协议从阿斯利康预付款1亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1},"content_text":"Jacobio Pharmaceuticals Group Co., Ltd. (JACOBIO-B) disclosed that its indirect non-wholly owned subsidiary, Beijing Jacobio, has received an upfront payment of USD100.00 million from AstraZeneca AB. The payment forms part of the Licence and Collaboration Agreement signed on 21 December 2025 for the global development of the pan-KRAS inhibitor JAB-23E73.\nAccording to the announcement dated 30 March 2026, the funds will increase the group’s cash reserves and support subsequent development of its oncology pipeline, which spans KRAS, STING, P53 and MYC pathways. Jacobio operates R&D centres in Beijing, Shanghai and Boston, leveraging its Induced Allosteric Drug Discovery Platform and immunostimulatory antibody-drug conjugate platform.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}